• Explore /
  • Poster
  • / Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors.

Safety of BI 754111, an anti-LAG-3 monoclonal antibody (mAb), in combination with BI 754091, an anti-PD-1 mAb, in patients with advanced solid tumors.

Abstract Poster

Authors

null

Melissa Lynne Johnson

Sarah Cannon Research Institute, Nashville, TN

Melissa Lynne Johnson , Manish R. Patel , Mohamad Cherry , Yoon-Koo Kang , Kensei Yamaguchi , Do-Youn Oh , Maen A. Hussein , Shigehisa Kitano , Shunsuke Kondo , Aaron Richard Hansen , Ivor John Percent , Ben George , Edward Arrowsmith , Manabu Morimoto , Christine Duffy , Miaomiao Ge , Maren Rohrbacher , Mabrouk M. Elgadi , Johanna C. Bendell

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT03156114, NCT03433898, NCT03697304, NCT03780725

Citation

J Clin Oncol 38: 2020 (suppl; abstr 3063)

DOI

10.1200/JCO.2020.38.15_suppl.3063

Abstract #

3063

Poster Bd #

127

Abstract Disclosures

Similar Posters

First Author: Kathleen N. Moore

First Author: Cai Zhou

First Author: Osama E. Rahma

Poster

2016 ASCO Annual Meeting

A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.

A first-in-human phase I study of the anti-PD-1 antibody PDR001 in patients with advanced solid tumors.

First Author: Aung Naing